Hans Biomed (042520.KQ) Stock Price

Hans Biomed Price

CLOSED
23,350.00KRW+600.00 (+2.60 %)
Market closed

Revenue has compounded at 14.1% per year over the past 19 years to 89.78 B KRW. Earnings per share have grown at 17.4% per year over the last 13 years. Hans Biomed's net margin stands at -34.9%, down from -30.9% several years earlier. Hans Biomed currently offers a dividend yield of about 0.51%. The payout ratio is around 16% of earnings. The dividend has grown at 9.1% per year over the past 10 years. The stock trades about 232% above its 52-week low.

Hans Biomed stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Hans Biomed over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Hans Biomed stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Hans Biomed's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Hans Biomed Stock Price History
DateHans Biomed Price
8/13/202623,350.00 KRW
8/12/202622,750.00 KRW
8/11/202624,200.00 KRW
8/10/202623,400.00 KRW
8/7/202621,650.00 KRW
8/6/202620,350.00 KRW
8/5/202620,400.00 KRW
8/4/202620,250.00 KRW
8/3/202618,990.00 KRW
7/31/202618,500.00 KRW
7/30/202618,040.00 KRW
7/29/202616,740.00 KRW
7/28/202618,670.00 KRW
7/27/202619,290.00 KRW
7/24/202619,700.00 KRW
7/23/202620,300.00 KRW
7/22/202620,600.00 KRW
7/21/202621,300.00 KRW
7/20/202620,600.00 KRW
7/16/202622,900.00 KRW
7/15/202624,900.00 KRW
7/14/202624,450.00 KRW
7/13/202626,600.00 KRW
7/10/202625,750.00 KRW
7/9/202623,900.00 KRW
7/8/202625,100.00 KRW
7/7/202625,550.00 KRW
7/6/202622,300.00 KRW
7/3/202622,800.00 KRW
7/2/202623,100.00 KRW
7/1/202624,600.00 KRW
6/30/202622,500.00 KRW
6/29/202624,950.00 KRW
6/26/202624,700.00 KRW
6/25/202626,650.00 KRW
6/24/202624,600.00 KRW
6/23/202622,000.00 KRW
6/22/202623,800.00 KRW
6/19/202624,500.00 KRW
6/18/202624,300.00 KRW
6/17/202626,750.00 KRW
6/16/202625,050.00 KRW
6/15/202624,200.00 KRW
6/12/202625,400.00 KRW
6/11/202625,750.00 KRW
6/10/202623,600.00 KRW
6/9/202624,100.00 KRW
6/8/202624,200.00 KRW
6/5/202628,450.00 KRW
6/4/202628,400.00 KRW
6/2/202626,300.00 KRW
6/1/202627,400.00 KRW
5/29/202629,100.00 KRW
5/28/202632,900.00 KRW
5/27/202634,800.00 KRW
5/26/202631,000.00 KRW
5/22/202628,800.00 KRW
5/21/202627,050.00 KRW
5/20/202628,950.00 KRW
5/19/202627,050.00 KRW
5/18/202623,900.00 KRW
5/15/202624,900.00 KRW
5/14/202627,900.00 KRW
5/13/202623,000.00 KRW
5/12/202623,600.00 KRW
5/11/202624,000.00 KRW
5/8/202625,200.00 KRW
5/7/202623,250.00 KRW
5/6/202629,500.00 KRW
5/4/202629,850.00 KRW
4/30/202629,400.00 KRW
4/29/202631,200.00 KRW
4/28/202631,100.00 KRW
4/27/202633,150.00 KRW
4/24/202630,200.00 KRW
4/23/202631,900.00 KRW
4/22/202633,450.00 KRW
4/21/202633,050.00 KRW
4/20/202633,300.00 KRW
4/17/202634,300.00 KRW
4/16/202634,700.00 KRW
4/15/202635,850.00 KRW
4/14/202634,750.00 KRW
4/13/202632,100.00 KRW
4/10/202631,300.00 KRW
4/9/202629,850.00 KRW
4/8/202632,000.00 KRW
4/7/202631,200.00 KRW
4/6/202633,050.00 KRW
4/3/202634,400.00 KRW
4/2/202636,900.00 KRW
4/1/202637,550.00 KRW
3/31/202633,700.00 KRW
3/30/202636,250.00 KRW
3/27/202641,100.00 KRW
3/26/202642,000.00 KRW
3/25/202643,350.00 KRW
3/24/202648,700.00 KRW
3/23/202648,700.00 KRW
3/20/202653,000.00 KRW
3/19/202655,700.00 KRW
3/18/202654,500.00 KRW
3/17/202643,950.00 KRW
3/16/202640,100.00 KRW
3/13/202642,600.00 KRW
3/12/202643,900.00 KRW
3/11/202642,700.00 KRW
3/10/202643,000.00 KRW
3/9/202644,250.00 KRW
3/6/202650,700.00 KRW
3/5/202646,150.00 KRW
3/4/202642,750.00 KRW
3/3/202648,000.00 KRW
2/27/202650,400.00 KRW
2/26/202650,500.00 KRW
2/25/202648,800.00 KRW
2/24/202645,800.00 KRW
2/23/202645,300.00 KRW
2/20/202649,000.00 KRW
2/19/202649,000.00 KRW
2/13/202642,800.00 KRW
2/12/202644,100.00 KRW
2/11/202642,100.00 KRW
2/10/202643,100.00 KRW
2/9/202644,600.00 KRW
2/6/202640,000.00 KRW
2/5/202643,900.00 KRW
2/4/202645,600.00 KRW
2/3/202644,300.00 KRW
2/2/202642,150.00 KRW
1/30/202639,500.00 KRW
1/29/202630,400.00 KRW
1/28/202627,600.00 KRW
1/27/202628,200.00 KRW
1/26/202628,200.00 KRW
1/23/202624,950.00 KRW
1/22/202624,400.00 KRW
1/21/202622,300.00 KRW
1/20/202622,450.00 KRW
1/19/202622,650.00 KRW
1/16/202623,400.00 KRW
1/15/202623,250.00 KRW
1/14/202623,050.00 KRW
1/13/202623,650.00 KRW
1/12/202623,850.00 KRW
1/9/202625,250.00 KRW
1/8/202626,150.00 KRW
1/7/202625,900.00 KRW
1/6/202627,000.00 KRW
1/5/202626,200.00 KRW
1/2/202626,500.00 KRW
12/30/202527,600.00 KRW
12/29/202530,100.00 KRW
12/26/202530,100.00 KRW
12/24/202530,100.00 KRW
12/23/202529,600.00 KRW
12/22/202530,300.00 KRW
12/19/202531,400.00 KRW
12/18/202533,800.00 KRW
12/17/202534,150.00 KRW
12/16/202532,500.00 KRW
12/15/202532,600.00 KRW
12/12/202533,450.00 KRW
12/11/202532,600.00 KRW
12/10/202532,650.00 KRW
12/9/202528,800.00 KRW
12/8/202525,800.00 KRW
12/5/202528,200.00 KRW
12/4/202528,150.00 KRW
12/3/202529,250.00 KRW
12/2/202529,000.00 KRW
12/1/202529,050.00 KRW
11/28/202531,000.00 KRW
11/27/202528,900.00 KRW
11/26/202528,850.00 KRW
11/25/202531,100.00 KRW
11/24/202535,050.00 KRW
11/21/202534,750.00 KRW
11/20/202534,950.00 KRW
11/19/202534,400.00 KRW
11/18/202532,200.00 KRW
11/17/202534,950.00 KRW
11/14/202528,900.00 KRW
11/13/202530,450.00 KRW
11/12/202530,200.00 KRW
11/11/202530,500.00 KRW
11/10/202530,550.00 KRW
11/7/202529,000.00 KRW
11/6/202529,650.00 KRW
11/5/202530,600.00 KRW
11/4/202528,000.00 KRW
11/3/202524,150.00 KRW
10/31/202526,850.00 KRW
10/30/202527,250.00 KRW
10/29/202528,000.00 KRW
10/28/202531,600.00 KRW
10/27/202533,300.00 KRW
10/24/202533,800.00 KRW
10/23/202533,800.00 KRW
10/22/202529,050.00 KRW
10/21/202527,200.00 KRW
10/20/202523,300.00 KRW
10/17/202523,000.00 KRW
10/16/202525,300.00 KRW
10/15/202520,350.00 KRW
10/14/202517,340.00 KRW
10/13/202518,870.00 KRW
10/10/202520,250.00 KRW
10/2/202521,400.00 KRW
10/1/202520,500.00 KRW
9/30/202518,170.00 KRW
9/29/202515,640.00 KRW
9/26/202513,160.00 KRW
9/25/202518,090.00 KRW
9/24/202518,100.00 KRW
9/23/202515,000.00 KRW
9/22/202515,500.00 KRW
9/18/202515,170.00 KRW
9/17/202514,730.00 KRW
9/16/202514,400.00 KRW
9/15/202514,320.00 KRW
9/12/202511,720.00 KRW
9/11/202511,260.00 KRW
9/10/202510,760.00 KRW
9/9/20259,390.00 KRW
9/8/20258,250.00 KRW
9/5/20257,590.00 KRW
9/4/20257,550.00 KRW
9/3/20257,350.00 KRW
9/2/20257,230.00 KRW
9/1/20257,030.00 KRW
8/29/20257,570.00 KRW
8/28/20257,670.00 KRW
8/27/20257,590.00 KRW
8/26/20257,630.00 KRW
8/25/20257,580.00 KRW
8/22/20257,630.00 KRW
8/21/20257,700.00 KRW
8/20/20257,730.00 KRW
8/19/20257,810.00 KRW
8/18/20257,820.00 KRW
Access this data via the Eulerpool API
Get Free API Key

Hans Biomed Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
80.10 B KRW
-3.41 B KRW
-17.84 B KRW
Jan 1, 2021
59.10 B KRW
-16.34 B KRW
-18.29 B KRW
Jan 1, 2022
74.46 B KRW
1.26 B KRW
6.15 B KRW
Jan 1, 2023
78.03 B KRW
-4.52 B KRW
-23.04 B KRW
Jan 1, 2024
81.14 B KRW
630.00 M KRW
-7.22 B KRW
Jan 1, 2025
89.78 B KRW
0.00 KRW
-31.34 B KRW
Jan 1, 2026 (e)
143.80 B KRW
9.09 B KRW
14.92 B KRW
Jan 1, 2027 (e)
201.50 B KRW
0.00 KRW
23.19 B KRW

Hans Biomed Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 8:54 AM
 
REVENUEB KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
EBITB KRW
EBIT MARGIN%
NET INCOMEB KRW
NET INCOME GROWTH%
DIV.KRW
DIV. GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
17.5820.0721.0323.4329.0539.0651.7566.9980.1059.1074.4678.0381.1489.78143.80201.50
17.1314.144.8211.3923.9834.4632.4929.4619.57-26.2225.994.803.9810.6560.1740.13
293.04256.7445.4945.5746.1846.8252.7159.9353.0849.4661.3557.8363.7857.3857.3857.38
51.5151.519.5710.6813.4118.2927.2840.1542.5229.2345.6845.1251.7551.5182.51115.62
3.153.893.905.065.889.256.0110.96-3.41-16.341.26-4.520.63–9.09–
17.9119.4118.5621.5920.2623.6711.6216.36-4.25-27.651.69-5.790.78–6.32–
2.523.433.504.914.637.834.029.95-17.84-18.296.15-23.04-7.22-31.3414.9223.19
223.6536.341.8640.38-5.7969.25-48.68147.70-279.302.51-133.61-474.88-68.66333.97-147.6155.43
70.00100.00100.00100.00100.00100.00100.00120.00120.00–––––124.46129.08
40.0042.86–––––20.00–––––––3.71
9.869.869.869.869.869.429.829.869.869.869.869.869.869.869.869.86
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Hans Biomed generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Hans Biomed retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Hans Biomed's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Hans Biomed has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Hans Biomed's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Hans Biomed stock margins

The Hans Biomed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hans Biomed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hans Biomed.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
53.08 %
-4.25 %
-22.27 %
Jan 1, 2021
49.46 %
-27.66 %
-30.95 %
Jan 1, 2022
61.35 %
1.69 %
8.26 %
Jan 1, 2023
57.83 %
-5.79 %
-29.53 %
Jan 1, 2024
63.78 %
0.78 %
-8.90 %
Jan 1, 2025
57.38 %
0.00 %
-34.91 %
Jan 1, 2026 (e)
57.38 %
6.32 %
10.38 %
Jan 1, 2027 (e)
57.38 %
0.00 %
11.51 %

Hans Biomed Stock Revenue, EBIT, Earnings per Share

The Hans Biomed earnings per share therefore indicates how much revenue Hans Biomed has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2021
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2022
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2023
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2024
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2025
0.00 KRW
0.00 KRW
0.00 KRW
Jan 1, 2026 (e)
11,072.61 KRW
921.64 KRW
1,149.00 KRW
Jan 1, 2027 (e)
15,515.52 KRW
0.00 KRW
1,786.00 KRW

Hans Biomed business model & stock analysis

Hans Biomed Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Hans Biomed historical P/E ratio, EBIT multiple, and P/S ratio

Hans Biomed annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Hans Biomed shares outstanding

The number of shares of Hans Biomed was 9.86 M in 2025. This indicates how many shares Hans Biomed is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
9.86 M Stocks
Jan 1, 2021
9.86 M Stocks
Jan 1, 2022
9.86 M Stocks
Jan 1, 2023
9.86 M Stocks
Jan 1, 2024
9.86 M Stocks
Jan 1, 2025
9.86 M Stocks
Jan 1, 2026 (e)
9.86 M Stocks
Jan 1, 2027 (e)
9.86 M Stocks

Hans Biomed Dividend History

11 years of dividend payments

YearAnnual DividendYoY ChangePayments
2020120.00KRW 0.0%—
2019120.00KRW↑ 20.0%1×
2018100.00KRW 0.0%1×
2017100.00KRW 0.0%1×
2016100.00KRW 0.0%1×
2015100.00KRW 0.0%1×
2014100.00KRW 0.0%1×
2013100.00KRW↑ 42.9%1×
201270.00KRW↑ 40.0%1×
201150.00KRW 0.0%1×

Hans Biomed dividend payout ratio

In 2025, Hans Biomed had a payout ratio of 15.91%. The payout ratio indicates the percentage of the company's profits that Hans Biomed distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
16.12 %
Jan 1, 2021
17.48 %
Jan 1, 2022
15.17 %
Jan 1, 2023
16.26 %
Jan 1, 2024
16.30 %
Jan 1, 2025
15.91 %
Jan 1, 2026 (e)
10.83 %
Jan 1, 2027 (e)
7.23 %
Price targets and forecasts for Hans Biomed are not yet available.

Hans Biomed shareholder structure

% Name
24.94916%
Hwang (Ho Chan)
Hwang (Ho Chan)
10.85054%
Osstem Implant Co., Ltd.
Osstem Implant Co., Ltd.
8.01920%
NP Growth 10th Private Equity Fund
NP Growth 10th Private Equity Fund
0.94109%
Hwang (Deok Gu)
Hwang (Deok Gu)
0.46200%
Mirae Asset Global Investments Co., Ltd.
Mirae Asset Global Investments Co., Ltd.
0.34650%
Kim (Geun Yeong)
Kim (Geun Yeong)

Hans Biomed Executives and Management Board

6 members · avg. age 52 · 0 % women

Management

GK

Mr. Geun Yeong Kim (59)

Chief Executive Officer, Director · since 2014

–
JL

Mr. Jong Hun Lee (43)

Assistant Managing Director

–

Board of Directors

CK

Mr. Chang Hui Kim (56)

Internal Auditor, Director

–
HH

Mr. Ho Chan Hwang (65)

Director · since 2020

–
JL

Mr. Jeong Bin Lee (34)

Other Non-Executive Director

–
SO

Mr. Sang Seok Oh (52)

Non-Executive Independent Director

–

Frequently asked questions about Hans Biomed

5 analysts currently rate the Hans Biomed stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Hans Biomed to generate revenue of 143.80 B KRW and earnings per share of 1,512.95 KRW.

Hans Biomed Analyst Price Targets 2026

Converted at the current exchange rate, the Hans Biomed share trades at 14.27 EUR (23,350.00 KRW).

No history available for Hans Biomed.

The expected revenue of Hans Biomed is 143.80 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Hans Biomed is 14.92 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Hans Biomed is currently 15.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hans Biomed stock.

The price-to-sales ratio (P/S) of Hans Biomed is currently 1.60. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hans Biomed stock.

The Eulerpool Quality Score for Hans Biomed is 2/10.

The ISIN of Hans Biomed is KR7042520007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Hans Biomed is 042520.KQ. The ticker symbol is used to trade Hans Biomed shares on the stock exchange.

Over the past 12 months, Hans Biomed paid a dividend of 120.00 KRW . This corresponds to a dividend yield of about 0.51 %. For the coming 12 months, Hans Biomed is expected to pay a dividend of 129.08 KRW.

The current dividend yield of Hans Biomed is 0.51 %.

Hans Biomed pays a dividend, distributed in the months of , , , .

Hans Biomed paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 129.08 KRW are expected. This corresponds to a dividend yield of 0.55 %.

Hans Biomed is assigned to the 'Health' sector.

To receive the latest dividend of Hans Biomed from amounting to 120 KRW, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Hans Biomed are distributed in KRW.

All fundamentals and in-depth analysis of Hans Biomed

Our stock analysis for Hans Biomed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hans Biomed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Hans Biomed Stock
Hans Biomed Revenue→
Hans Biomed Stock
Hans Biomed Net Income→
Hans Biomed Stock
Hans Biomed P/E→
Hans Biomed Stock
Hans Biomed P/S→
Hans Biomed Stock
Hans Biomed EBIT→
Hans Biomed Stock
Hans Biomed Dividend→
Hans Biomed Stock
Hans Biomed Directors Dealings→
Hans Biomed Stock
Hans Biomed Stocks→
Hans Biomed Stock
Hans Biomed Market capitalization→
Hans Biomed Stock
Hans Biomed Debt→
Hans Biomed Stock
Hans Biomed Liabilities→
Hans Biomed Stock
Hans Biomed Equity→
Hans Biomed Stock
Hans Biomed AAQS→
Hans Biomed Stock
Hans Biomed Employees→
Hans Biomed Stock
Hans Biomed ROE→
Hans Biomed Stock
Hans Biomed ROA→
Hans Biomed Stock
Hans Biomed ROCE→
Hans Biomed Stock
Hans Biomed News→
Hans Biomed Stock
Hans Biomed Analyst Price Targets→

Health Stocks

Hansa BiopharmaHanmi Science CoHanshang Group CoHanmi Pharm CoHansoh Pharmaceutical Group CompanyHangzhou Tigermed Consulting CoHapvida Participacoes e InvestimentosHangzhou TianMuShan Pharmaceutical Enterprise CoHarbin Fuerjia Technology CoHangzhou Biotest Biotech CoHARBIN GLORIA PHARMACEUTICALS CoHangzhou Bio-Sincerity Pharma-Tech CoAll Stocks A–Z →